Related Experiment Videos
Increased CSF F2-isoprostane concentration in probable AD.
T J Montine1, M F Beal, M E Cudkowicz
1Department of Pathology, Center for Molecular Neurosciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Neurology
|February 20, 1999
Summary
Elevated F2-isoprostane levels in cerebrospinal fluid (CSF) indicate increased oxidative damage in Alzheimer's disease (AD) but not in Amyotrophic Lateral Sclerosis (ALS). This suggests oxidative stress may be an early factor in AD pathogenesis.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Oxidative damage is implicated in neurodegenerative diseases like Alzheimer's disease (AD) and Amyotrophic Lateral Sclerosis (ALS).
- F2-isoprostanes are reliable biomarkers for in vivo lipid peroxidation.
- Previous studies indicated elevated F2-isoprostanes in postmortem CSF of AD patients.
Purpose of the Study:
- To quantify F2-isoprostane levels in cerebrospinal fluid (CSF) from patients with AD, ALS, and controls.
- To investigate the role of oxidative damage in the pathogenesis of AD and ALS.
Main Methods:
- CSF samples were collected from the lumbar cistern of patients and controls.
- F2-isoprostane concentrations were measured using gas chromatography/negative ion chemical ionization mass spectrometry.
Main Results:
- CSF F2-isoprostane levels were significantly elevated in patients with probable AD compared to controls.
- No significant increase in CSF F2-isoprostanes was observed in ALS patients compared to controls.
Conclusions:
- Elevated CSF F2-isoprostanes are not a universal marker of neurodegeneration.
- Increased brain oxidative damage may be an early event in the development of AD.